Quest Diagnostics (NYSE:DGX) Issues FY 2025 Earnings Guidance

Quest Diagnostics (NYSE:DGX - Get Free Report) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 9.550-9.800 for the period, compared to the consensus estimate of 9.710. The company issued revenue guidance of $10.7 billion-$10.9 billion, compared to the consensus revenue estimate of $10.8 billion.

Quest Diagnostics Stock Down 1.1 %

Shares of NYSE:DGX traded down $1.84 on Tuesday, reaching $165.49. The company had a trading volume of 769,212 shares, compared to its average volume of 878,346. The stock has a market capitalization of $18.37 billion, a P/E ratio of 21.52, a P/E/G ratio of 2.16 and a beta of 0.92. The stock has a 50-day moving average price of $165.45 and a 200 day moving average price of $158.73. Quest Diagnostics has a twelve month low of $125.42 and a twelve month high of $178.87. The company has a quick ratio of 1.02, a current ratio of 1.10 and a debt-to-equity ratio of 0.82.

Quest Diagnostics (NYSE:DGX - Get Free Report) last posted its earnings results on Thursday, January 30th. The medical research company reported $2.23 earnings per share for the quarter, topping the consensus estimate of $2.19 by $0.04. Quest Diagnostics had a return on equity of 15.07% and a net margin of 8.80%. On average, equities analysts expect that Quest Diagnostics will post 9.7 EPS for the current year.

Quest Diagnostics Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, April 21st. Investors of record on Monday, April 7th will be issued a dividend of $0.80 per share. This is an increase from Quest Diagnostics's previous quarterly dividend of $0.75. This represents a $3.20 annualized dividend and a dividend yield of 1.93%. The ex-dividend date is Monday, April 7th. Quest Diagnostics's dividend payout ratio is currently 41.61%.

Remove Ads

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Leerink Partners raised Quest Diagnostics from a "market perform" rating to an "outperform" rating and boosted their price objective for the stock from $169.00 to $174.00 in a research report on Monday, January 6th. Leerink Partnrs upgraded shares of Quest Diagnostics from a "hold" rating to a "strong-buy" rating in a research report on Monday, January 6th. Citigroup lowered Quest Diagnostics from a "buy" rating to a "neutral" rating and set a $185.00 price target on the stock. in a research note on Tuesday, March 4th. Barclays upped their price objective on shares of Quest Diagnostics from $168.00 to $175.00 and gave the stock an "equal weight" rating in a research note on Friday, January 31st. Finally, JPMorgan Chase & Co. increased their target price on Quest Diagnostics from $173.00 to $180.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Eight analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, Quest Diagnostics currently has a consensus rating of "Moderate Buy" and a consensus target price of $178.38.

Insider Transactions at Quest Diagnostics

In related news, SVP Michael E. Prevoznik sold 4,643 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $170.00, for a total transaction of $789,310.00. Following the completion of the transaction, the senior vice president now directly owns 38,117 shares of the company's stock, valued at approximately $6,479,890. This represents a 10.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Vicky B. Gregg sold 1,250 shares of the business's stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $164.57, for a total transaction of $205,712.50. Following the transaction, the director now owns 16,867 shares in the company, valued at approximately $2,775,802.19. The trade was a 6.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 14,157 shares of company stock valued at $2,423,755 over the last 90 days. 0.79% of the stock is owned by company insiders.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Quest Diagnostics stock. Brighton Jones LLC purchased a new position in shares of Quest Diagnostics Incorporated (NYSE:DGX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 2,144 shares of the medical research company's stock, valued at approximately $323,000. 88.06% of the stock is currently owned by hedge funds and other institutional investors.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.